woman1
Wednesday, March 25, 2026
23.1
C
Bengaluru
Hot topics
Partner Don’t Punish
Articles by Vivek Hattangadi, Genesh Kuriakose, Pankaj Mehrotra, Salil Kallianpur and Jay Mehta
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
Winning Sales Organization
"Digital in Pharma" Special Issue. Invitation to DigiStorm2017, How to Create a Winning Sales Organization and DigiPharmaX. Avail Early Bird Discount - details inside.
FLUX – Indian Pharma in the Post VUCA World
Introduction
For decades, leaders and organizations have relied on the...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
In the blistering Sonoran Desert, where temperatures regularly exceed...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
In the blistering Sonoran Desert, where temperatures regularly exceed...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
In the blistering Sonoran Desert, where temperatures regularly exceed...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
In the blistering Sonoran Desert, where temperatures regularly exceed...
Hot topics
Breaking Performance Barriers
Articles by K. Hariram, Pankaj Mehrotra, Rinkesh Shah, Gopal Kishore, Amaninder S. Dhillon, Ramandish Arora, Mohit Kumar Bhutani, Richa Goyal, and Mahendra Kumar Rai
Careers in Medical Device Companies
Key Insights
Thermo Fisher Scientific leads the industry with $42.88 billion...
Aflibercept: When Originators Stop Fighting and Start Licensing
When Regeneron Pharmaceuticals and Bayer AG signed a licensing...
Indian Pharma Market Highlights
Indian Pharma Market highlights for the month of October 2018, brought to you by AIOCD Pharma Softech Awacs.
National Seminar on UCPMP
The seminar will help companies especially Product Management Teams and Sales Teams to understand their changing roles due to UCPMP. It will also bring clarity on strategies and promotional inputs including CME's, sampling, gifts etc.
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
In the blistering Sonoran Desert, where temperatures regularly exceed...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
In the blistering Sonoran Desert, where temperatures regularly exceed...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
In the blistering Sonoran Desert, where temperatures regularly exceed...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
In the blistering Sonoran Desert, where temperatures regularly exceed...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
Newsletter
Get important news delivered directly to your inbox and stay connected!